Acadia, Neuren sign North American license deal for Rett syndrome treatment

Image: Acadia Pharmaceuticals and Neuren Pharmaceuticals have signed deal for the development and commercialization of trofinetide for Rett syndrome. Photo: courtesy of rawpixel on Unsplash.